Browsing by Author Ciruelos, Eva
Showing results 10 to 17 of 17
< previous
| Issue Date | Title | Author(s) |
|---|---|---|
| 18-Sep-2019 | Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial | Adamo, Barbara; Bellet Ezquerra, Meritxell; Paré, Laia; Pascual, Tomás; Vidal Losada, Maria Jesús; Pérez Fidalgo, José A.; Blanch, Salvador; Martínez, Noelia; Murillo, Laura; Gómez Pardo, Patricia; López González, Ana; Amillano, Kepa; Canes, Jordi; Galván, Patricia; González Farré, Blanca; Gonzalez, Xavier; Villagrasa, Patricia; Ciruelos, Eva; Prat Aparicio, Aleix |
| 1-Apr-2021 | Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL | Martin, M.; Zielinski, C.; Ruiz Borrego, M.; Carrasco, E.; Turner, N.; Ciruelos, Eva; Muñoz Mateu, Montserrat; Bermejo de las Heras, Begoña; Margelí Vila, Mireia; Anton, A.; Kahan, Z.; Csöszi, T.; Casas, M. I.; Murillo, L.; Morales, S.; Alba, Emilio; Gal Yam, E.; Guerrero Zotano, A.; Calvo, L.; Haba Rodríguez, J. de la; Ramos, M.; Álvarez López, Isabel; García Palomo, Andrés; Huang Bartlett, C.; Koehler, M.; Caballero, R.; Corsaro, M.; Huang, X.; García Sáenz, José Ángel; Chacón, José Ignacio; Swift, C.; Thallinger, C.; Gil Gil, Miguel |
| 11-Jul-2024 | Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response | Brasó-maristany, Fara; Ferrero-cafiero, Juan Manuel; Falato, Claudette; Martínez Sáez, Olga; Cejalvo, Juan Miguel; Margelí Vila, Mireia; Tolosa, Pablo; Salvador-bofill, Francisco Javier; Cruz, Josefina; González-farré, Blanca; Sanfeliu, Esther; Òdena, Andreu; Serra, Violeta; Pardo, Francisco; Luna Barrera, Ana María; Arumi, Miriam; Guerra, Juan Antonio; Villacampa, Guillermo; Sánchez Bayona, Rodrigo; Ciruelos, Eva; Espinosa-bravo, Martín; Izarzugaza, Yann; Galván, Patricia; Matito, Judit; Pernas, Sonia; Vidal, Maria; Santhanagopal, Anu; Sellami, Dalila; Esker, Stephen; Fan, Pang-dian; Suto, Fumitaka; Vivancos, Ana; Pascual, Tomás; Prat, Aleix; Oliveira, Mafalda |
| 20-Jan-2020 | Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade | Brasó Maristany, Fara; Griguolo, Gaia; Pascual, Tomás; Paré, Laia; Nuciforo, Paolo; Llombart Cussac, Antonio; Bermejo de las Heras, Begoña; Oliveira, Mafalda; Morales, Serafín; Martínez, Noelia; Vidal Losada, Maria Jesús; Adamo, Barbara; Martínez, Olga; Pernas, Sònia; López, Rafael; Muñoz Mateu, Montserrat; Chic Ruché, Núria; Galván, Patricia; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, Eduardo; Gregorio, Sara; Gomis, Roger R.; Villagrasa, Patricia; Cortés, Javier; Ciruelos, Eva; Prat Aparicio, Aleix |
| 28-Sep-2022 | Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial | Salvador Bofill, Javier; Moreno Anton, Fernando; Rodríguez Sánchez, César A.; Galve Calvo, Elena; Hernando Melia, Cristina; Ciruelos, Eva; Vidal Losada, Maria Jesús; Jiménez Rodriguez, Begoña; De La Cruz Merino, Luis; Martínez Jañez, Noelia; Villanueva Vazquez, Rafael; De Toro Salas, Ruben; Anton Torres, Antonio; Alvarez Lopez, Isabel Manuela; Gavila Gregori, Joaquin; Quiroga Garcia, Vanesa; Vicente Rubio, Elena; De La Haba Rodriguez, Juan; Gonzalez Santiago, Santiago; Diaz Fernandez, Nieves; Barnadas Molins, Agusti; Cantos Sanchez De Ibargüen, Blanca; Delgado Mingorance, Juan Ignacio; Bellet Ezquerra, Meritxell; De Casa, Sonia; Gimeno, Asuncion; Martin, Miguel |
| 9-Jan-2019 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial | Gavilá, Joaquín; Oliveira, Mafalda; Pascual, Tomás; Perez-Garcia, Jose; Gonzàlez, Xavier; Canes, Jordi; Paré, Laia; Calvo Serrano, Isabel; Ciruelos, Eva; Muñoz Mateu, Montserrat; Virizuela, Juan A.; Ruiz, Isabel; Andrés, Raquel; Perelló, Antonia; Martínez, Jerónimo; Morales, Serafín; Marín Aguilera, Mercedes; Martínez, Debora; Quero, Juan C.; Llombart-Cussac, Antonio; Prat Aparicio, Aleix |
| 23-Apr-2021 | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer | Pascual, Tomás; Oliveira, Mafalda; Ciruelos, Eva; Bellet Ezquerra, Meritxell; Saura, Cristina; Gavilá, Joaquin; Pernas, Sònia; Muñoz Mateu, Montserrat; Vidal Losada, Maria Jesús; Margelí Vila, Mireia; Cejalvo Andújar, Juan Miguel; González Farré, Blanca; Espinosa Bravo, Martin; Cruz, Josefina; Salvador Bofill, Francisco Javier; Guerra, Juan Antonio; Luna Barrera, Ana María; Arumi de Dios, Miriam; Esker, Stephen; Fan, Pang-dian; Martínez Sáez, Olga; Villacampa, Guillermo; Paré, Laia; Ferrero Cafiero, Juan M.; Villagrasa, Patricia; Prat Aparicio, Aleix |
| 1-Jul-2021 | The role of CDK4/6 inhibitors in early breast cancer | Gil Gil, Miguel; Alba, Emilio; Gavilá, Joaquín; Haba Rodríguez, Juan de la; Ciruelos, Eva; Tolosa, Pablo; Candini, Daniele; Llombart Cussac, Antonio |